A detailed history of Rock Springs Capital Management LP transactions in Merus N.V. stock. As of the latest transaction made, Rock Springs Capital Management LP holds 892,549 shares of MRUS stock, worth $40.1 Million. This represents 1.52% of its overall portfolio holdings.

Number of Shares
892,549
Previous 1,001,073 10.84%
Holding current value
$40.1 Million
Previous $59.2 Million 24.72%
% of portfolio
1.52%
Previous 1.84%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$47.19 - $58.84 $5.12 Million - $6.39 Million
-108,524 Reduced 10.84%
892,549 $44.6 Million
Q2 2024

Aug 14, 2024

SELL
$39.81 - $60.2 $5.79 Million - $8.76 Million
-145,487 Reduced 12.69%
1,001,073 $59.2 Million
Q1 2024

May 15, 2024

BUY
$28.03 - $51.82 $7.69 Million - $14.2 Million
274,491 Added 31.48%
1,146,560 $51.6 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $674,838 - $964,151
33,641 Added 4.01%
872,069 $24 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $7.24 Million - $9.82 Million
359,897 Added 75.21%
838,428 $19.8 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $8.77 Million - $13 Million
478,531 New
478,531 $12.6 Million
Q2 2018

Aug 14, 2018

SELL
$16.77 - $22.76 $2.93 Million - $3.98 Million
-174,917 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$16.07 - $19.87 $1.56 Million - $1.93 Million
-97,035 Reduced 35.68%
174,917 $3.24 Million
Q4 2017

Feb 14, 2018

SELL
$14.23 - $21.28 $43,373 - $64,861
-3,048 Reduced 1.11%
271,952 $5.28 Million
Q3 2017

Nov 14, 2017

BUY
$13.6 - $19.87 $3.74 Million - $5.46 Million
275,000
275,000 $5.46 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.06B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.